118 related articles for article (PubMed ID: 9068770)
1. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.
Armstrong M; Daly AK; Blennerhassett R; Ferrier N; Idle JR
Br J Psychiatry; 1997 Jan; 170():23-6. PubMed ID: 9068770
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
4. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.
Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K
Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906
[TBL] [Abstract][Full Text] [Related]
5. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
6. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.
Ellingrod VL; Schultz SK; Arndt S
Psychiatr Genet; 2000 Mar; 10(1):9-11. PubMed ID: 10909122
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
[TBL] [Abstract][Full Text] [Related]
10. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG
Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505
[TBL] [Abstract][Full Text] [Related]
11. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
Ellingrod VL; Schultz SK; Arndt S
Pharmacotherapy; 2002 Nov; 22(11):1416-9. PubMed ID: 12432967
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
15. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.
Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM
Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
17. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?
Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ
J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients.
Lam LC; Garcia-Barcelo MM; Ungvari GS; Tang WK; Lam VK; Kwong SL; Lau BS; Kwong PP; Waye MM; Chiu HF
Pharmacopsychiatry; 2001 Nov; 34(6):238-41. PubMed ID: 11778144
[TBL] [Abstract][Full Text] [Related]
19. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Lerer B; Nimgaonkar VL; Thelma BK
Schizophr Res; 2005 Jun; 75(1):21-6. PubMed ID: 15820320
[TBL] [Abstract][Full Text] [Related]
20. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.
Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA
Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
